Results 161 to 170 of about 4,268 (199)
Some of the next articles are maybe not open access.
Current Opinion in HIV and AIDS, 2018
Analyzing the evidence for the strand transfer integrase inhibitor cabotegravir (CAB; GSK744, GSK1265744), its properties and differences from other compounds in the class, as well as reviewing the preclinical and clinical evidence for its potential in antretroviral therapy and medical HIV prevention.CAB has been investigated both as an oral and an ...
Hans-Jürgen, Stellbrink +1 more
openaire +2 more sources
Analyzing the evidence for the strand transfer integrase inhibitor cabotegravir (CAB; GSK744, GSK1265744), its properties and differences from other compounds in the class, as well as reviewing the preclinical and clinical evidence for its potential in antretroviral therapy and medical HIV prevention.CAB has been investigated both as an oral and an ...
Hans-Jürgen, Stellbrink +1 more
openaire +2 more sources
Cabotegravir Plus Rilpivirine: First Approval
Drugs, 2020A regimen comprising extended release injectable suspensions of cabotegravir and rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV Healthcare and Janssen Pharmaceutica (Janssen) as a complete regimen for HIV infection. Based on the results of the ATLAS and FLAIR trials, the regimen was recently approved in Canada for the ...
openaire +2 more sources
Canadian Journal of Health Technologies
CADTH recommends that Apretude should be reimbursed by public drug plans for at-risk adults and adolescents aged 12 years and older and weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, if certain conditions are met.
openaire +2 more sources
CADTH recommends that Apretude should be reimbursed by public drug plans for at-risk adults and adolescents aged 12 years and older and weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, if certain conditions are met.
openaire +2 more sources
Cabotegravir long-acting for HIV-1 prevention
Current Opinion in HIV and AIDS, 2015Preexposure prophylaxis (PrEP) with daily Truvada has demonstrated clinical efficacy against HIV-1 acquisition that correlates with high adherence. Long-acting antiretroviral drugs offer an alternative to daily regimens and may improve PrEP adherence.
Chasity D, Andrews, Walid, Heneine
openaire +2 more sources
Open Forum Infectious DiseasesThe interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated by the lack of consensus on the threshold to consider. Building on real-world therapeutic drug monitoring data and documented virologic failures, this article ...
François R Girardin +2 more
exaly +2 more sources
Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
Expert Opinion on Investigational Drugs, 2018Human Immunodeficiency Virus (HIV) is a chronic infection that depletes the immune system of essential components causing those infected to be at risk for multiple life-threatening infections. Worldwide, millions live with this infection, the vast majority attributable to HIV-1.
Tristan D, McPherson +2 more
openaire +2 more sources
AIDS
In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence ...
Emma, Rubenstein +16 more
openaire +2 more sources
In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence ...
Emma, Rubenstein +16 more
openaire +2 more sources
Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV
Expert Review of Anti-Infective Therapy, 2022Elahe Taki, Mohsen Heidary, Arezoo asadi
exaly